Novo Nordisk A/S News - September 29, 2026

Novo Nordisk Licenses Hengrui’s Weekly Oral Obesity Drug in Up-to-$2.6B Deal

Novo Nordisk has signed an exclusive licensing agreement with Chinese drugmaker Hengrui Pharma for HRS-1596, an experimental once-weekly oral weight-loss drug...